| Q47934995 | A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect |
| Q64245253 | Characterization of SIRT1/DNMTs Functions and LINE-1 Methylation in Patients with Age-Related Macular Degeneration |
| Q37552056 | Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value |
| Q42375268 | Chromothripsis in Treatment Resistance in Multiple Myeloma |
| Q59447403 | Curcumin Modulates DNA Methyltransferase Functions in a Cellular Model of Diabetic Retinopathy |
| Q26769649 | Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive |
| Q50330020 | Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance |
| Q92479179 | Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies |
| Q37082758 | Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon |
| Q90694599 | Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma |
| Q40064607 | LINE-1 hypermethylation in white blood cell DNA is associated with high-grade cervical intraepithelial neoplasia. |
| Q34282505 | LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis |
| Q63977092 | Resveratrol Modulates SIRT1 and DNMT Functions and Restores LINE-1 Methylation Levels in ARPE-19 Cells under Oxidative Stress and Inflammation |
| Q38736249 | Risk Stratification in Multiple Myeloma |
| Q37248153 | Sequential model selection-based segmentation to detect DNA copy number variation |
| Q36439245 | The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. |
| Q36939043 | The molecular characterization and clinical management of multiple myeloma in the post-genome era. |
| Q52717229 | The multiple myelomas - current concepts in cytogenetic classification and therapy. |
| Q37946246 | The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma |
| Q88739454 | [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients] |